NCT03762876 (THEFLOW) is a clinical trial in Major Hepatectomy, sponsored by University Hospital Heidelberg.

Who is sponsoring NCT03762876?

NCT03762876 is sponsored by University Hospital Heidelberg.

What condition does NCT03762876 study?

NCT03762876 studies Major Hepatectomy.

Is NCT03762876 still recruiting?

NCT03762876 is currently status unknown. Last updated 15 October 2019.

Last reviewed 2019-10-15 · How we verify

NCT03762876: THEFLOW

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Trans-Hepatic Flow Changes in Major Hepatectomy

Status unknown Last updated 15 October 2019

What this trial tests

trial in Major Hepatectomy in 50 participants. Status unknown.

Timeline

25 March 2018

Primary endpoint
1 March 2020

1 July 2020

Quick facts

Lead sponsor	University Hospital Heidelberg
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	50
Start date	25 March 2018
Primary completion	1 March 2020
Estimated completion	1 July 2020
Sites	1 location across Germany

Conditions studied

Major Hepatectomy — all drugs for Major Hepatectomy →

Sponsor

University Hospital Heidelberg

Who can join

18 and older, any sex, with Major Hepatectomy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Changes in trans-hepatic flow after major and extended hepatectomy (EH) can lead to small for size and flow syndrome (SFSF), which is associated with a significantly higher rate of morbidity and mortality. The current therapies for SFSF are not effective because tissue damage following SFSF is usually irreversible and the liver parenchyma loses the ability to regenerate. Therefore, the best approach to improve patient survival is to predict SFSF and perform adequate intraoperative preventive procedures. Portal vein flow (PVF), hepatic artery flow (HAF), and portal vein pressure (PVP) are the main criteria for development of SFSF after living donor liver transplantation. The mechanisms that change trans-hepatic flow are similar after hepatectomy and living donor liver transplantation. Trans-hepatic flow is routinely measured during liver resection, but the effect of these changes on SFSF has not been studied. Identifying the factors that alter trans-hepatic flow after hepatectomy would allow hepatic inflow to be modulated before and after surgery, to prevent SFSF. Trans-hepatic flow and pressure parameters (PVF, HAF, and PVP) are routinely measured and monitored during liver resection. The aim of the proposed study is to analyze changes in these parameters after major hepatectomy and determine the factors that alter trans-hepatic flow after hepatectomy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Evaluation of the role of transhepatic flow in postoperative outcomes following major hepatectomy (THEFLOW): study protocol for a single-centre, non-interventional cohort study.
Golriz M, Lemekhova A, Khajeh E, Ghamarnejad O, et al · · 2019 · PMID 31604785 · DOI 10.1136/bmjopen-2019-029618

Verify or expand the search:

Other University Hospital Heidelberg trials

Trials by the same sponsor.

NCT07388147 — Exercise Therapy for Multiple Myeloma Patients · NA · not yet recruiting
NCT07348874 — Predictive Accuracy of Machine Perfusion for Kidney Transplant Outcomes in Germany · not yet recruiting
NCT07181928 — Is Mentalization-based Therapy More Effective Than Treatment-as-usual for Adolescents With Dissocial Disorders? · NA · not yet recruiting
NCT06954623 — Partial Breast Re-irradiation for Breast Cancer · NA · recruiting
NCT06913010 — DV 100 as a Framework for the Hospital Incident Command System · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03762876 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital Heidelberg
Last refreshed: 15 October 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03762876.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing